SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the pending FDA decision for Capricors Duchenne muscular dystrophy treatment deramiocel, with a letter from 28 HOPE-3 investigators urging approval and disputing the agencys interpretation of the trial data. Many traders are optimistic and discuss call activity and short-squeeze potential, while others stress that approval is uncertain and a rejection or delay remains possible.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias steep drop is part of a broader semiconductor selloff as traders weigh whether post-election calls for tighter data-center controls could slow AI infrastructure spending. The community is split between fears of a lasting AI-capex reset and dip buyers who argue the concerns are overblown and projects can shift elsewhere.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons quarterly results missed expectations and its full-year revenue outlook was cut, with federal procurement delays cited, driving a sharp selloff. Traders debate whether the reaction reflects weaker near-term growth and a rich valuation or creates a buying opportunity given the companys longer-term prospects.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A sharp selloff in semiconductor and AI-linked stocks has drawn attention to SOXS, as traders debate concerns about AI and data-center spending, sector valuations, and election-related policy uncertainty. Some expect more downside in chips, while others warn of a sharp rebound and note that SOXSs leverage and daily resets make it a volatile short-term trade.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas expected Q4 2026 Phase 3 APPROACH readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Bulls anticipate strong results and emphasize the add-on treatment approach, while skeptics question whether small Phase 2 findings will hold up and point to binary trial risk, potential dilution, and competition from other psychedelic therapies.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a sharp semiconductor selloff as traders worry that post-election scrutiny of data-center construction could slow AI infrastructure spending and chip demand. The community is split between viewing the drop as an overreaction and buying opportunity, and expecting further downside amid AI-bubble and memory-cycle concerns.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks shares are under pressure after its latest earnings, despite a strong quarter and raised full-year outlook. Traders are debating whether the selloff reflects profit-taking after a pre-earnings run or concerns about slower cloud net-new ARR growth and conservative forward guidance; some see a buying opportunity, while others question valuation and managements credibility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs quarterly results showed rapid growth in its AI cloud business and a large contracted backlog, but the rollout of its more than $4 billion annualized-revenue target was pushed to January or February after a customer design change. Traders are split between viewing the results and customer prepayments as a basis for a rebound and focusing on execution delays, heavy capital needs and debt amid a broader selloff in AI-infrastructure stocks.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

A broad market selloff, led by tech and semiconductor weakness, has weighed on the Dow as traders debate whether political pushback could slow AI and data-center investment. The community is largely bearish after the sharp decline, though some see the Dows relative resilience and rotation away from tech as a buying opportunity.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMAs strong third-quarter results, led by accelerating ASCENIV growth and a higher earnings outlook, drove a sharp rally. Traders largely welcomed the results and discussed a possible rerating or short-covering, while some questioned inventory and receivables levels and whether the growth can continue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCTX’s Bria-IMT™ named 2026 Immunotherapy Solution of the Year demonstrating median survival of 13.3-16.6 months in Phase 2 studies versus historical benchmarks of 5.9-9.8 months. Clinical validation + Phase 3 catalyst = one to watch. #Biotech 
 
NEWS: https://bit.ly/4Ad0M12

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World...

GlobeNewswire News Room

BriaCell Awarded 2026 "Immunotherapy Solution of the Year" By BioTech Breakthrough

StockTwits Web

BriaCell Therapeutics Corp

’s Bria-IMT™ named 2026 Immunotherapy Solution of the Year demonstrating median survival of 13.3-16.6 months in Phase 2 studies versus historical benchmarks of 5.9-9.8 months. Clinical validation + Phase 3 catalyst = one to watch. 